Roth Capital Reiterates Buy On Sarepta Therapeutics Following 3Q:14 Update
Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $22, which represents a potential upside of 36% from where the stock is currently trading.
Chattopadhyay noted, “Patient dosing in the pivotal study is set to commence during the 3rd week of November. Given the noise surrounding Sarepta’s program and eteplirsen’s safety profile (to date), we believe the DMD community is fully aware and the study is likely to enroll rapidly. Hence, Sarepta should be able to meet the FDA’s new mandate to include an additional three month safety data with an NDA submission during mid-15, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -11.7% and a 28.3% success rate. Chattopadhyay has a -25.5% average return when recommending SRPT, and is ranked #3316 out of 3364 analysts.